Wu Guosheng, Cruz Ruy J
1 Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA.
Transplantation. 2015 Jun;99(6):1265-72. doi: 10.1097/TP.0000000000000488.
Retransplantation is a viable treatment option for patients with primary intestinal graft loss.
We analyzed outcomes of retransplantations (n = 23) in adults from May 2000 to May 2010 at our center and compared patients who received liver-free retransplantations (n = 13) with those who received liver-inclusive retransplantations (n = 10).
The overall survival rates at 1, 3, and 5 years in retransplantations were 90.9%, 67.1%, and 59.7% (patient) and 82.2%, 58.6%, and 51.3% (graft), respectively, which were similar to the rates in primary transplants. The patient survival rates at 1, 3, and 5 years were 91.7%, 55.6%, and 41.7%, respectively, in liver-free retransplantations, as compared to rates of 90.0%, 80.0%, and 80.0% in liver-inclusive retransplantations. The graft survival rates at 1, 3, and 5 years in liver-free retransplantations were 76.2%, 40.6%, and 27.1%, respectively, which were significantly worse than those in liver-inclusive retransplantations (P = 0.03). Within an average follow-up of 32.3 months, 8 of 13 (61.5%) of liver-free retransplantations underwent enterectomy because of severe acute cellular rejection (n = 3) or chronic rejection (n = 5). Six of 13 (46.2%) recipients succumbed to rejection-related complications. Compared to liver-free retransplantations, the rate and severity of acute rejection were markedly de creased in liver-inclusive retransplantations, and no chronic rejection was seen. Within an average follow-up of 44.5 months, two of 10 (20%) died due to graft-versus-host disease and infection, respectively.
A liver-inclusive retransplantation offers a better long-term patient and graft survival, suggesting that including the liver as part of an intestinal graft should be considered in adult recipients when retransplantation is necessary.
再次移植是原发性肠移植失败患者可行的治疗选择。
我们分析了2000年5月至2010年5月在本中心进行的成人再次移植(n = 23例)的结果,并将接受无肝再次移植(n = 13例)的患者与接受含肝再次移植(n = 10例)的患者进行了比较。
再次移植患者1年、3年和5年的总体生存率分别为90.9%、67.1%和59.7%,移植物生存率分别为82.2%、58.6%和51.3%,与初次移植的生存率相似。无肝再次移植患者1年、3年和5年的生存率分别为91.7%、55.6%和41.7%,而含肝再次移植患者的生存率分别为90.0%、80.0%和80.0%。无肝再次移植患者1年、3年和5年的移植物生存率分别为76.2%、40.6%和27.1%,显著低于含肝再次移植患者(P = 0.03)。在平均32.3个月的随访期内,13例无肝再次移植患者中有8例(61.5%)因严重急性细胞排斥反应(n = 3例)或慢性排斥反应(n = 5例)接受了肠切除术。13例受者中有6例(46.2%)死于与排斥反应相关的并发症。与无肝再次移植相比,含肝再次移植的急性排斥反应发生率和严重程度明显降低,且未见慢性排斥反应。在平均44.5个月的随访期内,10例含肝再次移植患者中有2例分别死于移植物抗宿主病和感染。
含肝再次移植可提供更好的患者和移植物长期生存率,这表明在有必要进行再次移植时,成年受者应考虑将肝脏作为肠移植的一部分。